Intranasal Ketamine for Acute Pain by Rocchio, Robert J. & Ward, Kristina E.
University of Rhode Island 
DigitalCommons@URI 
Pharmacy Practice Faculty Publications Pharmacy Practice 
2021 
Intranasal Ketamine for Acute Pain 
Robert J. Rocchio 
Kristina E. Ward 
Follow this and additional works at: https://digitalcommons.uri.edu/php_facpubs 
The University of Rhode Island Faculty have made this article openly available. 
Please let us know how Open Access to this research benefits you. 
This is a pre-publication author manuscript of the final, published article. 
Terms of Use 
This article is made available under the terms and conditions applicable towards Open Access 
Policy Articles, as set forth in our Terms of Use. 
REVIEW ARTICLE 
 
Intranasal Ketamine for Acute Pain 
 
Robert J. Rocchio1, Kristina E. Ward1* 
 
University of Rhode Island, Department of Pharmacy Practice1 
 
*Corresponding Author: Kristina E. Ward, Clinical Professor and Vice Chair of Pharmacy Practice, 
University of Rhode Island, 7 Greenhouse Road, Suite 295J, Kingston, RI 02881, Office: (401) 874-
7484; E-mail: kward@uri.edu 
 
Financial Support: None 
 
Running Head: Intranasal ketamine for acute pain.  
 




















 To review current evidence regarding the off-label use of intranasal ketamine for acute pain 
presenting in the setting of the emergency department, and secondary to pediatric limb injuries, renal 
colic, digital nerve block, and migraines.  
Results 
 In all five indications reviewed, ketamine demonstrated efficacy in reducing pain. However, 
when compared to other agents, ketamine did not demonstrate superiority over opioids in pediatric 
limb injuries or renal colic and was not as efficacious as standard therapy for migraine relief.  
Ketamine was also associated with a greater incidence of transient adverse reactions, such as dizziness, 
bitter aftertaste, fatigue, and vomiting than opioid therapies.   
Discussion 
 The current body of evidence is insufficient to support the use of intranasal ketamine over other 
standard therapies for acute pain. However, current evidence can be used when developing dosing 
strategies, preparing for adverse reactions, and generating hypotheses for future, more robust research. 











 Between 2010 and 2017, opioids prescribed in the United States, in proportion to the 
population, has decreased by 12.8%.1 The downward trend may indicate an increased responsibility 
and burden on prescribers to combat the current opioid epidemic; especially since prescribed opioids 
are involved in 36% of all opioid overdose-related deaths.1  
 Providing analgesic treatment for patients experiencing pain is important, despite the backlash 
against opioids. However, judgment of whether or not to use opioid therapy can be difficult. In busy 
settings, such as the emergency department (ED), providers have to quickly determine whether a 
patient’s pain warrants opioid-induced analgesia or treatment with prescription strength non-steroidal 
anti-inflammatory drugs (NSAIDs). Other non-opioid medications with powerful analgesic effects may 
be an attractive option for providers.   
 Profound analgesic and anesthetic properties of phenylcyclidine (PCP), also known as “Angel 
Dust”, prompted scientific investigation into phenylcyclidine derivatives.  Researchers sought a 
molecule that would retain its desired properties, sans its psychotomimetic effects.  An early derivative 
produced in the mid-1960’s was CI-581, which later became known as ketamine.2 Evidence presented 
below explores research related to the intranasal form of ketamine and acute pain.  
Definition of Acute Pain 
 A consensus report on management of acute pain, put forth by American Academy of Pain 
Medicine, defines acute pain using four characteristics: existence of an event responsible for pain 
occurrence, sudden onset, temporary duration, and potential ability to develop into other pathological 
conditions.3  
Ketamine Pharmacology and Pharmacokinetics 
 Ketamine is a racemic mixture of (S)- and (R)-ketamine. Both enantiomers are non-competitive 
antagonists of the N-methyl-D-aspartate (NMDA) receptor and interact with other receptors, such as μ-
opioid receptors, monoaminergic receptors, muscarinic receptors, and γ-aminobutyric acid (GABA) 
receptors.4 Inhibition of NMDA receptors and activation of opioid and GABA receptors inhibit 
neuronal cell signaling, resulting in termination of pain transmission. However, activation of 
monoaminergic receptors is associated with inhibitory or excitatory effects on neuronal cells involved 
in pain transmission, depending on the specific receptor activated.5 The (S)-ketamine enantiomer, 
otherwise known as esketamine, has a fourfold higher affinity to the NMDA receptor than (R)-
ketamine.6,7  
 Ketamine retained the analgesic and anesthetic properties of phenycyclidine. However, 
psychomimetic and psychodysleptic effects still remain.2-4 At higher doses, ketamine produces 
dissociative anesthesia; a state in which a patient cannot respond to external stimuli, despite 
maintaining relatively normal respiratory and cardiovascular function.  Its mechanism producing 
dissociation is not well documented in current literature; however, ketamine’s selective inhibition of the 
brain’s limbic sensory association pathways is speculated as the cause.6 ⁠ 
 Patients report hallucinations, confusion, and other non-specific dissociative symptoms upon 
awaking from ketamine-induced anesthesia. Called emergence reactions, their occurrence has limited 
ketamine’s use as an anesthetic and analgesic agent.3,4  
 When administered intranasally, ketamine’s bioavailability is 45-50%. Once in circulation, 
ketamine undergoes N-demethylation by cytochrome P-450 3A4 to the active metabolite, norketamine, 
which is reported to have only one-third of the anesthetic properties of ketamine. Half-life of ketamine 
is two to four hours in adults and approximately 1.5 hours in children. Half-life of norketamine is 12 
hours.7 
Ketamine’s Role in the ED for Acute Pain 
 As a non-opioid analgesic, ketamine offers pain relief to patients with a known history of opioid 
abuse and misuse, and to patients who may not tolerate opioid side effects and adverse reactions.  
Additionally, intranasal ketamine’s ease of administration could allow medical staff to quickly treat a 
patient’s pain without the need to locate intravenous access. These properties position intranasal 
ketamine as a useful analgesic in the ED, provided it is efficacious in reducing pain. A systematic 
review8 identified ten studies that evaluated intranasal ketamine and intranasal esketamine’s efficacy in 
treating acute pain in the ED.  Studies consisted of both adult and pediatric patient populations.  Out of 
ten included studies, four were randomized controlled trials,9–12 four were observational studies,13–16 
one was a nonrandomized controlled trial,17 and the last was a case series.18 Seven of the studies are 
referenced in additional detail in the sections below.9,11-16 All ten studies found ketamine to be effective 
in reducing pain and the results of each are summarized in Table 1.9–18  
 Authors highlighted the need for additional randomized, controlled trials to measure efficacy of 
ketamine for treating acute pain in adults. Currently, only two observational studies14,16 have evaluated 
intranasal ketamine’s ability to reduce pain for adults presenting to the ED.  Dosing strategies for both 
trials are listed in Table 2. The two studies are useful as references for adverse reactions and dosing for 
future research, but do not offer clinically meaningful results.  Additional evidence is necessary to 
establish intranasal ketamine’s efficacy for reducing pain in adults before its use can be more widely 
recommended. 
Pediatric Limb Injuries  
 Children presenting to the ED, especially those under two years of age, are more likely to be 
under-treated with opioid analgesic medication than adults.19 Provider apprehension regarding 
respiratory depression or risk of a child developing opioid dependence have been reported as drivers of 
analgesic medication underuse.19 Unlike opioids, ketamine is not commonly associated with respiratory 
depression. Decreased risk of respiratory depression garners attention towards its use in pediatric 
patients, since opioid-induced respiratory depression may have fatal consequences if undetected.  
 In a quasi-experiment,15 effectiveness of intranasal ketamine for reducing pain in 28 children 
between 3 to 13 years old presenting to the ED with painful limb injuries was evaluated. Intranasal 
ketamine was initially dosed at 0.85 mg/kg with an additional dose 15 minutes after the first at 0.5 
mg/kg if pain control was inadequate, despite an initial dose of 0.75 mg/kg specified in study methods. 
The second dose was provided to patients at provider discretion.  Primary outcome was pain reported 
on a Faces Pain Scale – Revised (FPS-R) for children ages 3 to 6 years old and a 100 mm visual analog 
score (VAS) for children who were 7 to 13 years old 30 minutes after the initial administration of 
intranasal ketamine. No patients were assigned to a control. Ketamine was effective in reducing pain 
from limb injuries on both the FPS-R and VAS 30 minutes after initial administration. Mean baseline 
pain, taken before ketamine administration was 74.5 mm (interquartile range (IQR) = 60 to 85mm), 
while pain 30 minutes after administration was 30 mm (IQR = 12 to 51.5 mm, p < 0.001). Average total 
ketamine dose was 1 mg/kg.  The study is limited by its small sample size, use of two different scales 
for pain measurement, and lack of a control group.15 Since effects of intranasal ketamine were not 
compared to control, the dosing strategy outlined in the study methods was later used in two 
randomized, controlled trials to compare intranasal ketamine to intranasal fentanyl for limb pain.9,12 
 One of the two randomized, controlled trials enrolled children that were between 3 and 13 years 
of age,9 while the other enrolled older children, from 4 to 17 years of age.12 Both trials compared one 
dose 1 mg/kg of ketamine to 1.5 mcg/kg of fentanyl. Primary outcomes were rates of adverse reactions 
within 60 minutes after ketamine administration for the trial that enrolled older children9 and the 
change from baseline for pain recorded 30 minutes after administration in the trial enrolling a younger 
population.12  Pain at baseline and at 20 and 60 minutes after medication administration was also 
measured using VAS in the study enrolling older children.9 
 The study of older children enrolled 87 participants.  Frequency of adverse effects was 2.2 
times greater for children receiving ketamine versus fentanyl. All adverse effects, summarized in Table 
3, were transient and mild. The most common adverse effects reported in patients who received 
ketamine were bad taste in mouth, dizziness, tiredness and drowsiness.  Absolute risk differences for 
adverse effect rate when compared to fentanyl were significant for bad taste and dizziness, but not 
tiredness nor drowsiness (risk difference (RD) =68%, 95% CI, 53 to 84%; RD = 59%; 95% CI, 41 to 
76%; RD = 10%; 95% CI, –11% to 31%; and RD =7%; 95% CI, –6 to 21%, respectively). Additionally, 
intranasal ketamine was found to be as effective as intranasal fentanyl in reducing pain. No significant 
difference in pain reduction between either agent was determined in the trial enrolling older children at 
20- or 60-minutes using VAS (mean difference (MD) = 9 mm; 95% confidence interval (CI), –5 to 23 
mm and MD = -2 mm; 95% CI, –16 to 13 mm, respectively).  Adverse effect reporting was a limitation 
since drowsiness and tiredness were recorded as two different effects.  Children may not articulate their 
symptoms well enough for investigators to determine if they should be recorded as drowsiness or 
tiredness. Additionally, children towards the lower end of the included age range may struggle to 
communicate any adverse effects they experience; especially when under the effect of a psychoactive 
substance.9 
 The study that enrolled a younger pediatric population evaluated pain at baseline and at 15-, 
30-, and 60-minutes post-intervention using VAS for children age 11 to 17 and FPS-R for children age 
4 to 10.  The study cohort contained 73 participants; all of whom received 10 mg/kg of ibuprofen pre-
intervention.  No significant difference in pain score reductions was found between the ketamine and 
fentanyl groups at 15, 30 or 60 minutes post-intervention (median difference (MedD) = 0 mm; 95% CI, 
-20 to 20 mm; MedD = 5 mm; 95% CI, -10 to 20 mm; and MedD = 0 mm; 95% CI,  -13 to 13 mm, 
respectively) or in proportion of patients with a decreased VAS or FPS-R greater than or equal to 20 
mm (MedD = 1 mm;  95% CI, -20 to 22; MedD = 3; 95% CI, -16 to 22; and MedD = 9; 95% CI, -8 to 
27, respectively).  Participants who received ketamine reported a greater number of adverse effects 
than those in the fentanyl group (78 versus 40, respectively). The most commonly reported adverse 
effects for patients who received ketamine were bad taste in mouth, drowsiness, and dizziness.  Trial 
limitations include use of ibuprofen before administration of fentanyl or ketamine, which makes it 
impossible to determine what amount of pain reduction is attributed to either fentanyl or ketamine 
alone.  Additionally, patient pain was recorded through two different scales. Data was combined from 
both scales to achieve adequate power for the study’s analysis. Differences in responses between scales 
reduced the study’s internal validity.12  
 An additional study, PRIME,20 was a randomized, controlled, non-inferiority trial comparing 
intranasal ketamine and intranasal fentanyl.  Investigators stated that previous dosing strategies in other 
trials evaluating intranasal ketamine were too conservative but did not describe how their dosing 
protocol was developed. Ketamine was dosed at 1.5 mg/kg while fentanyl was dosed at 2 mcg/kg.  The 
study cohort consisted of 90 participants who were between 8 to 17 years of age.  Primary outcome was 
reduction in pain from baseline to 30 minutes post-intervention. Pain scores were recorded using VAS.  
Non-inferiority margin was set to 10 mm, which is validated as the minimally important difference in 
VAS in children. 
 Intranasal ketamine was declared non-inferior to intranasal fentanyl.  At 15-, 30-, and 60-
minutes post-intervention, no significant difference in pain reduction from baseline was found between 
the ketamine and fentanyl groups (MD = 0.93; 95% CI, -6.09 to 7.96; MD = 1.26; 95% CI, -6.19 to 
8.71; and MD = 1.30; 95% CI, -7.36 to 9.95, respectively). All adverse effects reported were mild and 
transient and were found at higher rates in the ketamine group (relative risk (RR) = 2.5; 95%CI, 1.5 to 
4.0).  The most common adverse effects for those in the ketamine group were dizziness, unpleasant 
taste, and drowsiness.  Study limitations include a maximum dose supplied of 100 mcg of fentanyl and 
100 mg of ketamine.  Patients who weighed greater than 50 kg or 67 kg were unable to receive a full 
dose of fentanyl or ketamine, respectively. However, investigators attested that differences in pain 
reduction between patients who were under-dosed versus those who received a full dose of ketamine or 
fentanyl were not significant.20 
 Based on the available data in pediatric limb injuries, intranasal ketamine may represent a 
potential option for providers although quantity and quality of data is limited.  Adverse effects seem 
more common with intranasal ketamine compared to opioid controls, but of potential lesser severity. 
Nephrolithiasis 
 Further research analyzed the analgesic effects of intranasal ketamine for specific etiologies of 
pain. One such etiology, nephrolithiasis, is associated with excruciating pain and occurs in 19% of men 
and 9% of women. Renal colic involves uretal passage of the mass.21  Pharmacologic agents used in 
treatment of renal colic focus on providing pain relief.21–23 Medications used include injectable non-
steroidal anti-inflammatory drugs (NSAIDs) and injectable opioids.21 Recently, two randomized 
controlled trials were conducted to determine if intranasal ketamine may be also be an effective 
analgesic agent for renal colic.  
 In the first trial,22 40 patients were randomized to receive intranasal ketamine or intravenous 
(IV) morphine upon presentation to the ED with renal colic. Ketamine and morphine were individually 
dosed for patients using 1 mg/kg body weight and 0.1 mg/kg body weight, respectively. Placebo was 
administered IV or intranasally via the double-dummy technique.  Pain experienced by patients was 
recorded using a VAS determined pre-intervention and at 5-, 10-, and 30-minutes post-intervention. 
Patients who received ketamine had significantly greater pain at baseline and at 5 minutes after 
receiving treatment (MD = -0.95 mm; 95% CI, -1.75 to -0.14 mm; and MD = -0.79 mm; 95% CI, -1.48 
to -0.10, respectively).  However, ketamine closed the initial gap in VAS scores with morphine as it did 
not demonstrate significant differences in recorded pain at 15- and 30-minutes post-intervention once 
adjusted for baseline discrepancies (MD = -0.36; 95% CI, -1.08 to 0.34; and MD = -0.15; 95% CI, -
1.02 to 0.71, respectively).  Limiting the trial, a significant difference in baseline pain between the 
ketamine and morphine groups was present. Additionally, only 15% of patients in the morphine group 
were women, while 40% of patients in the ketamine group were women. Lastly, trial results are not 
generalizable to the U.S. population since all 40 subjects were patients presenting to one of two ED’s in 
Iran.22 
 A similar, but larger, study that evaluated efficacy of intranasal ketamine for treating pain 
secondary to renal occlusion was conducted in 130 patients presenting to the ED for renal colic also in 
Iran.23 However, the comparator differed; 1 mg/kg of intranasal ketamine was compared to 1 mcg/kg of 
intravenous fentanyl.  As with the study comparing ketamine to morphine,22 blinding was conducted 
via the double dummy technique. Both intranasal and intravenous placebos consisted of distilled water;  
a limitation, since administration of distilled water via intranasal or IV routes induces pain.  Pain was 
recorded on a VAS scale before medication administration and at 5-, 15-, and 30-minutes post-
treatment. Both groups had significant reductions in VAS scores over the 30-minute interval (p < 
0.001).  Mean reduction in VAS, as well as mean VAS at baseline, and at 5-, 15-, and 30-minutes post 
treatment were not provided.  Average pain reported was greater in the fentanyl group before treatment 
and at 5- and 15-minutes post-intervention, but no statistical significance for mean difference in pain 
was provided by the investigators.  No significant difference in pain was found between ketamine and 
fentanyl at 30 minutes (p = 0.449).  At conclusion of the 30-minute interval, 32.3% of patients in the 
ketamine and 9.2% of patients in the fentanyl group required additional analgesic medications (p = 
0.002).23  Trial limitations include use of a placebo that directly induced pain, not providing assessment 
of statistical significance for all outcomes, and not providing baseline characteristics for each treatment 
arm.  Since mean differences in VAS for the time intervals were not reported, not enough information 
is available to determine clinically meaningful differences in pain.23 
 Data supporting use of intranasal ketamine for renal colic associated with nephrolithiasis is 
sparse.  Assessment of effect on pain control is challenging since only one study presented data for pain 
control at multiple time points which showed an initial lesser response than the intravenous, opioid 
comparator.  Use of intranasal ketamine for renal colic seems premature. 
Digital Nerve Block  
 To address another specific cause of pain, digital nerve block with injectable anesthetic 
medications is used in preparation for certain procedures, such as toenail removal, removal of foreign 
objects, and drainage of digital infections.11,24,25 However, the actual injection procedure is reported to 
be painful.  One study evaluated application of ice to reduce pain from digital nerve block before 
administration of the anesthetic.  Ice was effective in reducing needle-stick pain, however other 
pharmacologic agents may be desired for greater pain relief.25 
 One study evaluated the use of intranasal ketamine to reduce pain related to digital nerve block 
in 100 patients.11 The study took place in the ED of a 100 bed hospital in Iran.  Patients were 
randomized to receive either 50 mg of intranasal ketamine or a matching volume of intranasal placebo.  
All adults scheduled to receive digital nerve block were eligible for inclusion.  Exclusion criteria 
included altered mental status, signs of decompensated heart failure, pregnancy, systolic blood pressure 
greater than 180 mmHg or diastolic blood pressure greater than 80 mmHg, and use of a prescription 
opioid within 24 hours.  Patient reported pain was recorded using VAS. Measurements were taken at 
baseline, immediately after, and 45 minutes after administration of local anesthetic.  
Median baseline pain scores were reported as 50 mm in ketamine treatment group and 49 mm 
in placebo group (95% CI 42.5 to 53 mm and 47 to 48 mm, respectively; p = 0.19).  Median pain 
scores taken immediately after digital nerve block were 28.5 mm in the ketamine treated group and 
47.5 mm in the placebo treated group (95% CI 24 to 32 mm and 40 to 52 mm, respectively; p < 0.001). 
Lastly, median pain scores 45 minutes after performing the nerve block were 21.5 mm in the treatment 
arm and 43.5 mm in the placebo arm (95% CI 17 to 25 mm and 32 to 42 mm, respectively; p < 0.001). 
 Ketamine was superior to placebo for alleviating pain associated with digital nerve block. 
However, pain induced by digital nerve block versus pain secondary to the original injury was not 
differentiated. Patients only reported one pain score at three different intervals for their overall 
perception of pain. Therefore, conclusions can only be drawn regarding the reduction in total pain for 
patients who undergo a digital nerve block procedure. Other study limitations include a small sample 
size from a singular hospital in Iran and a lack of blinding for those administering the intranasal 
medication.  The study results are not generalizable to a broader population.11 Future studies with larger 
and more diverse populations are warranted to establish whether intranasal ketamine use during digital 
nerve block represents a clinical improvement over current methods of pain control. 
Migraines  
 Finally, research has evaluated intranasal ketamine’s potential role for treating acute pain in 
patients suffering from episodes of migraine with auras. Two small, randomized, controlled trials 
evaluated the efficacy of intranasal ketamine for migraine relief.26,27 Inclusion and exclusion criteria for 
both studies are summarized in Table 4.  
 The first trial compared the efficacy of 25 mg of intranasal ketamine versus 2 mg of intranasal 
midazolam for pain secondary to migraines with aura. Midazolam was chosen as a control to maintain 
blinding, since both ketamine and midazolam have psychotropic effects. However, midazolam is not a 
standard treatment for migraines with aura and was not expected to provide relief. The studied cohort 
consisted of 18 individuals.  Recruited subjects were asked to complete and submit a survey for 6 
migraine with aura episodes that they had experienced over a two-year study window.  All symptoms 
recorded in the survey were ranked from 0 to 3, with 3 being the most severe and 0 being no 
symptoms.  Subjects self-administered their nasal spray at symptom onset for three of six episodes.  
Subjects were not dispensed dosages of intranasal therapy that could be used for the remaining 3 
episodes. Use of supplementary over-the-counter analgesics or prescription prophylaxis therapy was 
permitted for all patients throughout the study.  Results indicated that ketamine significantly reduced 
severity of migraine with aura (p = 0.032), however midazolam failed to demonstrate any effect on 
migraine severity (p=0.2).  
 The study was small and its dataset was incomplete, since 10 out of the 18 subjects had missing 
data.  Additionally, subjects may have saved their intranasal medication for more severe migraine 
episodes, which would result in greater baseline severity in the intranasal treatment arm. Lastly, 
subjects were asked to record their migraine experience during an exacerbation. Patients who had 
experienced especially severe migraine episodes may have been unable to complete the survey, which 
would exclude the worst migraine cases from the analysis. Patients who completed the survey were 
doing so under the effect of a psychoactive agent, which also could decrease response.26 
 The second trial27 included patients with any type of primary migraine.  A total of 53 subjects 
were enrolled and consisted of patients presenting to the ED with migraines warranting treatment with 
parenteral therapy. Patients were randomized to receive either standard therapy (25 mg of 
diphenhydramine and 10 mg of metoclopramide in 1000 mL normal saline IV) plus up to two 
administrations of saline nasal spray or placebo standard therapy (1000 mL normal saline IV without 
diphenhydramine or metoclopramide) plus up to two administrations of ketamine nasal spray. First 
dose of intranasal ketamine was 0.75 mg/kg (max 75 mg) and second dose was 0.25 mg/kg (max 25 
mg). Primary outcome was pain 30 minutes after medication administration, which was reported via 
VAS.  
 Statistical analysis failed to demonstrate any difference between ketamine and standard therapy 
in VAS scores for pain 30 minutes after administration of therapy or on a verbal numerical rating scale 
for pain at ED discharge (MD = 6.8; 95% CI, -5.8 to 19.4). Study limitations include a lack of blinding 
for providers who prescribed and administered ketamine or standard therapy, a small sample size, and 
providers were permitted to administer 30 mg of IV ketorolac or 10 mg of IV dexamethasone as 
additional therapy to the control group. Ketorolac was provided to 21 out of 26 patients, while 
dexamethasone was provided to 7 out of 26 patients in the control group.27 
 Overall, no substantial evidence supports intranasal ketamine’s role in migraine relief. Other 
evidence evaluating IV ketamine has also demonstrated ineffective treatment of pain related to 
migraines. A randomized, controlled trial found no significant difference between IV ketamine and IV 
saline placebo for migraine relief.28 Based on current literature, ketamine should not be used in place of 
standard therapy for the treatment of migraines.   
Discussion 
 Intranasal ketamine has demonstrated efficacy in reducing acute pain for patients at home and 
who are presenting to the ED. Compared to opioids, ketamine demonstrates non-significant differences 
in analgesic efficacy, but does demonstrate greater rates of minor and transient adverse effects. 
Dizziness, bitter after-taste, fatigue and vomiting are the most commonly reported adverse effects of 
ketamine. Overall quantity of evidence supporting intranasal ketamine’s use for specific etiologies of 
pain is insufficient to support its use over other standard therapies but should not preclude its 
consideration. Intranasal ketamine shows promise for patients who are at risk for opioid use disorder, 
opioid tolerance, or who are at risk for respiratory depression. Furthermore, practitioners in the ED 
setting may feel more comfortable administering intranasal ketamine to pediatric patients presenting 
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Table 1. Summary of Publications Regarding Use of Intranasal Ketamine in the ED7 





• N = 80†† 
• Mean difference in pain reduction for children presenting 
to the ED  with limb injuries was non-significant after ad-
ministration of ketamine or fentanyl 
• 15 minutes after: MD = 5 mm, 95% CI = -10 to 20 
• 30 minutes after: MD = 0 mm, 95% CI = -20 to 20 
• 60 minutes after: MD = 0 mm, 95% CI = -13 to 13 
Nejati et 
al10 
RCT Placebo • N = 100 
• Median pain scores taken immediately after digital nerve 
block were 28.5 mm in the ketamine group and 47.5 mm 
in the placebo group (p<0.001).  
• Median pain scores 45 minutes after performing the nerve 
block were 21.5 mm in the treatment arm and 43.5 mm in 





• N = 87 
• Absolute risk difference was significant for rate of bad 
taste in mouth (RD =68%; 95% CI, 53 to 84%) and dizzi-
ness (RD = 59%; 95% CI, 41 to 76%)  
• No significance was found for rates of tiredness (RD = 
10%; 95% CI,  –11% to 31%) or drowsiness (RD =7%; 
95% CI, –6 to 21%) 
• No significant difference in pain reduction was determined 
in pain reduction at 20 or 60 minutes (MD = 9 mm; 95% 
CI, –5 to 23; MD = -2 mm; 95% CI, –16 to 13, respec-
tively) 
Parvizrad9 RCT Ketamine 
IV 
• N = 154 
• 30 minutes post-ketamine administration, mean reported 
pain scores were 31.5 mm in the intranasal ketamine group 
and 29.35 in the IV ketamine group (p < 0.005) 
Nielsen et 
al16 
NRCT‡‡ None • N = 50 
• Median reported pain score for children who underwent 
any painful procedure was 3.1 mm (IQR 2.0–4.9) after ad-
ministration of ketamine/sufentanyl 
Andolfatto 
et al12 
Obs▿▿ None • N = 40 




Obs None • N = 28 
• Median pain at enrollment was reduced from 74.5 mm to 
30 mm at 30 minutes (p < 0.001) 
Yeaman et 
al (2014)13 
Obs None • N = 72 
• Ketamine dosed at 1 mg/kg was effective in reducing pain 
in 56% of patients 
• 56% of patients reported pain score reductions ≥ 20 mm 
(95% CI, 44.0 to 66.7) 
Shrestha et 
al15 
Obs None • N = 39 
• 79% of adults patients (n = 34) experienced pain relief 
(>20 mm on VAS)  15 minutes after intranasal ketamine 
administration, while 100% of patients experienced pain 
relief after 30 and 60 minutes.  
Johansson 
et al17 
CS➢ None • N = 34 
• Evaluated reduction in pain after administration of intrana-
sal esketamine 
• Pain scores decreased more than 20 mm 15 minutes after 
ketamine administration in 80% of patients 
• Median pain reduction at 30 minutes was 50 mm (inter-
quartile range = 40 to 70) 
‡Differences in pain presented as reduction in VAS reported pain score, unless otherwise noted 
†Randomized controlled trial (RCT) 
†† Number of patients included in study analysis 
‡‡Non-randomized clinical trial (NRCT) 
▿▿Observational study (Obs) 
➢Case Series (CS) 
  
Table 2: Dosing Strategies for Studies Evaluating Ketamine in Acute Adult Pain in the ED 
Study Dosing Strategy 
Yeaman et al 
(2014)13 
• First 6 months of this study: 0.7 mg/kg dose of ketamine.   
• Second 6 months of study: 1.0 mg/ kg of ketamine 
• Additional intranasal doses of 0.5 mg/ kg were provided over the course of the 
study† 
Shrestha et al 
(2016)15 
• Initial dose: 0.7 mg/kg  
• Optional:  additional 0.3 mg/kg dose 15 minutes after the initial administra-
tion‡ 
†The trial investigators did not provide information regarding why and when the additional doses of intranasal ketamine 
0.5mg/kg were administered.  
‡The additional 0.3mg/kg dose was provided upon patient request.  
  
Table 3: Rates of Adverse Effects within 60 Minutes After Administration of Intranasal Ketamine8 
Adverse Effect  
(> 2% frequency) 
Frequency 




Itchy nose 24% 
Visual disturbance 10% 
Nausea 7% 
  
Table 4: Inclusion and Exclusion Criteria for Studies Evaluating Migraine Relief  
Study Inclusion Criteria Exclusion Criteria 
Benish et al 
(2019)26 
• 18-65 years old 
• Pain between 5-10 
on a 0-10 verbal re-
sponse scale 
• Primary headache 
syndrome 
• Symptoms warrant 
parenteral analgesia 
• Weight <45 kg or >115 kg 
• Altered mental status 
• Focal neurological deficit 
• History of psychiatric illness 
• Heart rate <50 BPM or >150 beats per minute 
• Respiratory rate <8 or >30 breaths per minute 
• Allergy to any studied agent or ingredient  
• History of drug use 
• Alcohol abuse glaucoma  
• Intracranial hypertension 
• Ischemic heart disease 
• HIV 
• Immunosuppression 
• Renal disease requiring dialysis 
• Liver disease 
• Poorly controlled thyroid disease 
• Active bleeding or current use of anticoagulants  
Afridi et al 
(2013)25 
• History of aura du-
rations of ≥ 3 hours  
• Progression of aura 
from onset to 
• Pregnant women 
• History of asthma 
• History of psychiatric disorders 
• History of cardiac disorders  
maximal disability 
to be greater than 10 
minutes  
 
